Smaller companies set for third-quarter catalysts
The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.
ERA-EDTA 2021 – Novartis’s iptacopan sets the bar in rare kidney disease
Novartis makes progress with its most valuable pipeline asset, but others also hope to make a mark in IgA nephropathy.
Medtronic’s Hugo still a long way from victor
The world’s biggest medtech expects great things from its new surgical robot, but its best shot at leading a market with a new product remains renal denervation.
AHA 2020 – sotagliflozin wins come too late for Lexicon
But the Soloist trial suggests a benefit in heart failure with preserved ejection fraction, which might be good news for Lexicon’s SGLT2 rivals.
Gout flop leaves Sobi red-faced
SEL-212 fails to beat Krystexxa in phase II, but why did Sobi pay $100m for the asset in June and then put it into phase III?
ESC 2020 – Farxiga impresses in chronic kidney disease
In Dapa-CKD, Farxiga-treated patients without diabetes did numerically better than those with diabetes.
Obseva shows why red flags are worth heeding
A crucial second pivotal trial in uterine fibroids fails to dispel concerns about the company’s linzagolix.
Myovant socks it to Orilissa
Two years after Abbvie’s disappointing launch of Orilissa Myovant hails the development of something much better.
